FMK

• Description :

  FMK is a an irreversible RSK2 kinase inhibitor, that covalently modifies the C-terminal kinase domain of RSK.

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Ribosomal S6 Kinase (RSK)

• Type :

  Reference compound

• Related Pathways :

  MAPK/ERK Pathway

• Applications :

  Cancer-Kinase/protease

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/FMK.html

• Concentration :

  10mM

• Purity :

  99.83

• Solubility :

  DMSO : 50 mg/mL (ultrasonic)

• Smiles :

  FCC(C1=C(C2=C(N=CN=C2N1CCCO)N)C3=CC=C(C=C3)C)=O

• Molecular Formula :

  C18H19FN4O2

• Molecular Weight :

  342.37

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Cuello F, et al. Evidence for direct regulation of myocardial Na+/H+ exchanger isoform 1 phosphorylation and activity by 90-kDa ribosomal S6 kinase (RSK) : effects of the novel and specific RSK inhibitor fmk on responses to alpha1-adrenergic stimulation.|[2]Bain J, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408 (3) :297-315.|[3]Kang S, et al. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell. 2007 Sep;12 (3) :187-9.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, stored under nitrogen)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  RSK2

• CAS Number :

  [821794-92-7]